Cargando…

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions

BACKGROUND: Chronic myeloid leukaemia (CML) is one of the most well characterised human malignancies. Most patients have a cytogenetically visible translocation between chromosomes 9 and 22 which generates the pathognomonic BCR::ABL1 fusion gene. The derivative chromosome 22 (‘Philadelphia’ or Ph ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	May, Philippa C., Reid, Alistair G., Robinson, Mark E., Khorashad, Jamshid S., Milojkovic, Dragana, Claudiani, Simone, Willis, Fenella, Apperley, Jane F., Innes, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369825/ https://www.ncbi.nlm.nih.gov/pubmed/37496024 http://dx.doi.org/10.1186/s12920-023-01607-7

Ejemplares similares

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
por: Claudiani, Simone, et al.
Publicado: (2019)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

FISH mapping of Philadelphia negative BCR/ABL1 positive CML
por: Virgili, Anna, et al.
Publicado: (2008)

Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia
por: Hoelbl, Andrea, et al.
Publicado: (2010)

Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
por: Claudiani, Simone, et al.
Publicado: (2021)

Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients
por: Nandagopalan, S. Rajashree, et al.
Publicado: (2016)

Synthesis of the l- and d-SH2 domain of the leukaemia oncogene Bcr-Abl
por: Schmidt, Nina, et al.
Publicado: (2022)

An unusual case of high hyperdiploid childhood ALL with cryptic BCR/ABL1 rearrangement
por: Lizcova, Libuse, et al.
Publicado: (2014)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association
por: Faizan, Mahwish, et al.
Publicado: (2021)

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
por: Cook, Lucy B., et al.
Publicado: (2022)

Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients
por: Osman, Emad-Aldin I., et al.
Publicado: (2010)

Stem cell and kinase activity-independent pathway in resistance of leukaemia to BCR-ABL kinase inhibitors
por: Li, Shaoguang, et al.
Publicado: (2007)

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)
por: Gallipoli, Paolo, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia
por: Warsch, Wolfgang, et al.
Publicado: (2012)

Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukaemia treated with TKIs or at diagnosis
por: Liu, Jingjing, et al.
Publicado: (2020)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation
por: Qin, R, et al.
Publicado: (2014)

EVI1 expression in childhood acute lymphoblastic leukaemia is not restricted to MLL and BCR/ABL rearrangements and is influenced by age
por: Stevens, A, et al.
Publicado: (2014)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Cryptic e1a2 BCR-ABL1 Fusion With Complex Chromosomal Abnormality in de novo Myelodysplastic Syndrome
por: Seo, Bo-Young, et al.
Publicado: (2015)

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy
por: Luatti, Simona, et al.
Publicado: (2017)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
por: Virgili, Anna, et al.
Publicado: (2010)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Potential Role of Notch Signalling in CD34(+) Chronic Myeloid Leukaemia Cells: Cross-Talk between Notch and BCR-ABL
por: Aljedai, Abdullah, et al.
Publicado: (2015)

BCR::ABL1-like acute lymphoblastic leukaemia: a single institution experience on identification of potentially therapeutic targetable cases
por: Płotka, Anna, et al.
Publicado: (2023)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
por: Eiring, Anna M., et al.
Publicado: (2015)

Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach
por: Busch, Caroline, et al.
Publicado: (2023)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bjo73iv7qe0uj1m4epvln84o2r